Cullinan Associates Inc. Has $17.72 Million Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Cullinan Associates Inc. raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 2.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 275,978 shares of the biopharmaceutical company’s stock after acquiring an additional 7,794 shares during the quarter. Bristol-Myers Squibb makes up about 1.2% of Cullinan Associates Inc.’s investment portfolio, making the stock its 16th largest position. Cullinan Associates Inc.’s holdings in Bristol-Myers Squibb were worth $17,715,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Psagot Investment House Ltd. increased its position in Bristol-Myers Squibb by 4.6% during the third quarter. Psagot Investment House Ltd. now owns 4,038 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 178 shares during the period. Archford Capital Strategies LLC increased its position in Bristol-Myers Squibb by 0.8% during the fourth quarter. Archford Capital Strategies LLC now owns 23,810 shares of the biopharmaceutical company’s stock worth $1,528,000 after acquiring an additional 189 shares during the period. Weaver Consulting Group increased its position in Bristol-Myers Squibb by 3.5% during the third quarter. Weaver Consulting Group now owns 5,906 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 200 shares during the period. Community Bank of Raymore increased its position in Bristol-Myers Squibb by 2.6% during the fourth quarter. Community Bank of Raymore now owns 8,005 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 200 shares during the period. Finally, First Personal Financial Services increased its position in Bristol-Myers Squibb by 7.7% during the third quarter. First Personal Financial Services now owns 2,831 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 202 shares during the period. Hedge funds and other institutional investors own 83.02% of the company’s stock.

Shares of Bristol-Myers Squibb stock opened at $66.58 on Thursday. The firm has a market capitalization of $108.25 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 0.85 and a beta of 0.73. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.83 and a quick ratio of 3.72. The company’s fifty day moving average price is $62.52 and its two-hundred day moving average price is $53.03. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $67.09.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.11. The firm had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.09 EPS. Analysts predict that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be issued a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. Bristol-Myers Squibb’s payout ratio is 45.23%.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the sale, the senior vice president now owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the sale, the insider now directly owns 31,963 shares in the company, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

BMY has been the topic of a number of research reports. Gabelli initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, November 27th. They set a “buy” rating on the stock. ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 19th. Mizuho initiated coverage on shares of Bristol-Myers Squibb in a research report on Monday, November 25th. They set a “buy” rating on the stock. UBS Group boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Finally, Bank of America initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Buy” and an average target price of $61.69.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: Closed-End Mutual Funds

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.